LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

LLY

1,042.27

-1.11%↓

JNJ

246.2

+0.25%↑

ABBV

228.42

-0.4%↓

NVS

166.68

+1.33%↑

MRK

123.89

+0.15%↑

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

98.73 2.66

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

94.62

Максимум

99.13

Ключови измерители
By Trading Economics
Приходи	-6.3M -53M
Продажби	2.8M 51M
EPS	-0.82
Марж на печалбата	-103.131
Служители	283
EBITDA	-7.6M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+49.37% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.1B 6.4B
Предишно отваряне	96.07
Предишно затваряне	98.73

Настроения в новините

By Acuity

64%

36%

315 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.02.2026 г., 23:07 ч. UTC

Печалби

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 23:01 ч. UTC

Печалби

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:59 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24.02.2026 г., 22:42 ч. UTC

Печалби

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24.02.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24.02.2026 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24.02.2026 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24.02.2026 г., 23:30 ч. UTC

Пазарно говорене

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24.02.2026 г., 23:20 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.02.2026 г., 23:16 ч. UTC

Печалби

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24.02.2026 г., 23:13 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24.02.2026 г., 23:12 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24.02.2026 г., 23:10 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24.02.2026 г., 23:08 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24.02.2026 г., 23:07 ч. UTC

Печалби

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24.02.2026 г., 22:52 ч. UTC

Печалби

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24.02.2026 г., 22:46 ч. UTC

Печалби

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24.02.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Warner Receives New Bid From Paramount -- 3rd Update

24.02.2026 г., 22:29 ч. UTC

Печалби

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24.02.2026 г., 22:28 ч. UTC

Печалби

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24.02.2026 г., 22:27 ч. UTC

Печалби

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24.02.2026 г., 22:25 ч. UTC

Печалби

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24.02.2026 г., 22:24 ч. UTC

Печалби

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24.02.2026 г., 22:23 ч. UTC

Печалби

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths Interim Dividend 45 Australian Cents/Share

24.02.2026 г., 22:22 ч. UTC

Печалби

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24.02.2026 г., 22:21 ч. UTC

Печалби

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

49.37% нагоре

12-месечна прогноза

Среден 143.92 USD 49.37%

Висок 167 USD

Нисък 125 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

315 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.